A bioactive flavonoid polyphenol (3,7,3',4'-tetrahydroxyflavone) found predominantly in strawberries (160 μg/g), apples, persimmons, onions, and cucumbers. In cPNI, fisetin is clinically significant as a competitive inhibitor of catechol-O-methyltransferase (COMT), a senolytic agent that selectively clears senescent cells, and a modulator of neuroinflammatory pathways through NF-κB suppression and neurotrophic factor upregulation.
Imagine a city sanitation department with two jobs: managing the dopamine traffic (neurotransmitter flow through brain streets) and clearing out abandoned buildings (senescent cells). Fisetin acts like a traffic cop who slows down the dopamine cleanup crew (COMT is the enzyme that breaks down dopamine, like a street sweeper). By inhibiting this sweeper, dopamine stays in circulation longer—more time for signals to get where they need to go, improving attention and mood without producing more dopamine.
But fisetin also moonlights as a demolition specialist. It walks through the city looking for abandoned, toxic buildings—old cells that should have died but didn't (senescent cells). These buildings leak inflammatory garbage into the neighbourhood (inflammaging). Fisetin doesn't touch healthy buildings, but when it finds a senescent one, it triggers the demolition sequence (apoptosis), clearing space for new construction. Unlike a sledgehammer approach that damages everything, fisetin is a precise urban renewal program—it preserves catecholamine function while selectively removing cellular debris.
Fisetin competitively binds to the catechol-binding site of COMT, blocking the enzyme's ability to methylate catecholamines:
COMT + S-adenosyl methionine (SAM) → methylated catecholamine + S-adenosylhomocysteine
Fisetin disrupts this by:
- Competitive inhibition at the substrate-binding domain (IC50 ≈ 2.3 μM for soluble COMT)
- Prolonging half-life of dopamine (from ~1-2 min to ~5-8 min in synaptic cleft)
- Extending action of norepinephrine and epinephrine at adrenergic receptors
- Reducing formation of 3-methoxytyramine (dopamine metabolite) and normetanephrine
This mechanism is particularly relevant in individuals with COMT Val158Met polymorphism (rs4680), where Val/Val genotype already shows high enzyme activity and rapid catecholamine degradation.
graph TD
A[Fisetin exposure] --> B[p53 upregulation]
A --> C[BCL-2 family modulation]
B --> D[Pro-apoptotic pathway activation]
C --> D
D --> E[BNIP3/BNIP3L mitophagy]
D --> F[Caspase-3/7 activation]
E --> G[Mitochondrial clearance]
F --> G
G --> H[Senescent cell apoptosis]
I[Senescent cell baseline] --> J[SASP secretion]
J --> K[IL-6, IL-8, MMP secretion]
K --> L[Chronic inflammation]
H --> M[Reduced SASP]
M --> N[Resolution of inflammaging]
Fisetin induces senolytic activity through:
- Upregulation of p53 in senescent but not healthy cells
- Inhibition of anti-apoptotic proteins: BCL-2, BCL-xL downregulation
- Activation of pro-apoptotic proteins: BAX, BAK, BNIP3 upregulation
- Mitochondrial pathway: cytochrome c release → caspase-9 → caspase-3/7
- Selective toxicity: requires 20-100 μM concentrations for senolytic effect (achievable with supplementation but not dietary intake alone)
¶ Neuroprotective and Anti-inflammatory Mechanisms
Fisetin → Sirtuin-1 activation → deacetylation of NF-κB p65 subunit → reduced NF-κB nuclear translocation → decreased expression of:
Parallel pathway:
Fisetin → PI3K/Akt activation → GSK-3β inhibition → CREB phosphorylation → BDNF transcription (2-4 fold increase in hippocampal neurons)
Additional effects:
- MAPK pathway modulation: ERK1/2 phosphorylation → NGF expression
- Antioxidant induction: Nrf2 activation → HO-1, SOD, catalase upregulation
- Glutamate toxicity protection: NMDA receptor modulation, reduced calcium influx
Fisetin is particularly relevant for patients with COMT Val/Val genotype (high enzyme activity), which correlates with:
- Faster dopamine degradation → reduced prefrontal cortex dopamine → executive dysfunction, ADHD-like symptoms
- Lower pain threshold (reduced descending inhibition via noradrenergic pathways)
- Increased stress sensitivity (rapid adrenaline clearance)
Clinical application: Fisetin supplementation (100-500 mg/day) can functionally mimic the Met/Met genotype without genetic intervention, enhancing cognitive function, mood, and pain modulation. This is a key example of nutritional genomics in cPNI—using diet to compensate for genetic vulnerability.
Critical warning from Module 8: In patients with COMT Met/Met polymorphism (slow enzyme activity, already high catecholamine levels), fisetin and other COMT inhibitors (Quercetin, Rutin, Luteolin, EGCG) can precipitate catecholamine excess syndromes (anxiety, insomnia, tachycardia, hypertension). Do not give COMT-inhibiting polyphenols without genotyping or symptom screening.
Senescent cells accumulate with age (0.5-2% of total cells by age 60-80), secreting the senescence-associated secretory phenotype (SASP):
- Pro-inflammatory cytokines: IL-6 (up to 50-fold increase), IL-8, TNF-α
- Matrix metalloproteinases: MMP-3, MMP-9 → tissue degradation
- Growth factors: VEGF, TGF-β → fibrosis
Fisetin clearance of senescent cells reduces:
- Chronic low-grade inflammation (baseline IL-6 from 3-5 pg/mL to 1-2 pg/mL in mouse models)
- Tissue fibrosis (improved elasticity in lung, liver, adipose tissue)
- Age-related functional decline (improved physical function in elderly mice equivalent to 10-year human rejuvenation)
Dosing for senolytic effect:
- Dietary fisetin: 10-50 μg/day (strawberries, apples) — insufficient for senolytic action
- Supplemental fisetin: 100-500 mg/day for 2-3 consecutive days per month (intermittent dosing matches research protocols)
- Bioavailability challenge: fisetin has poor water solubility; liposomal or emulsified forms improve absorption
Fisetin addresses multiple cPNI metamodel layers:
- Metamodel 0 (Evolutionary mismatch): Modern diet lacks high polyphenol intake from wild plants; supplementation compensates
- Metamodel 1 (Chronic low-grade inflammation): Senolytic action directly reduces inflammatory load
- Metamodel 2 (Neuro-endocrine-immune interface): COMT inhibition modulates catecholamine-immune crosstalk
- Metamodel 3 (Selfish systems): Supports neuroplasticity and cognitive function (brain pull) while reducing systemic inflammation (immune system demands)
¶ Contraindications and Interactions
- COMT Met/Met genotype: avoid or use minimal doses
- Catecholamine-sensitive conditions: anxiety disorders, panic, ADHD with hyperarousal
- Drug interactions: potentiates effect of MAO inhibitors, SSRIs, stimulants (additive catecholamine enhancement)
- Pregnancy/lactation: insufficient safety data for senolytic doses
- Dietary sources: Strawberries (160 μg/g), apples (26 μg/g), persimmons (10 μg/g), onions (5 μg/g)
- COMT inhibition IC50: 2.3 μM for soluble COMT, 0.9 μM for membrane-bound COMT
- Senolytic dose threshold: 20-100 μM tissue concentration (requires 100+ mg oral supplementation)
- Dopamine half-life extension: from 1-2 minutes to 5-8 minutes with COMT inhibition
- BDNF enhancement: 2-4 fold increase in hippocampal expression (in vitro, 10 μM fisetin)
- NF-κB suppression: 40-60% reduction in nuclear translocation (in activated microglia)
- Bioavailability: <5% oral bioavailability due to poor water solubility and extensive first-pass metabolism
- Senescent cell selectivity: induces apoptosis in senescent fibroblasts at 10 μM but requires >50 μM for healthy cell toxicity
- Clinical trial dosing: 100 mg/day × 2 days per month in human longevity studies
- COMT Val158Met interaction: Val/Val carriers show greatest cognitive benefit from fisetin; Met/Met carriers risk catecholamine excess
- COMT — fisetin is a competitive inhibitor prolonging catecholamine action by blocking methylation
- dopamine — extended synaptic half-life improves prefrontal executive function and reward processing
- norepinephrine — prolonged action enhances descending pain inhibition and attention
- epinephrine — reduced degradation increases stress resilience but can trigger anxiety in slow COMT variants
- senescent cells — senolytic mechanism selectively induces apoptosis via p53 and BCL-2 family modulation
- inflammaging — SASP reduction lowers chronic inflammatory burden in aging tissues
- BDNF — upregulated via CREB phosphorylation supporting hippocampal neuroplasticity
- NGF — increased through ERK1/2 MAPK pathway activation in neurons
- NF-κB — inhibited via Sirtuin-1-mediated deacetylation reducing inflammatory gene transcription
- neuroplasticity — enhanced through neurotrophic factors and reduced neuroinflammation
- cognitive function — improved attention, working memory, and processing speed via dopaminergic enhancement
- Chronic low-grade inflammation — reduced through senolytic action and NF-κB suppression
- polyphenols — member of flavonoid subclass with catechol structure enabling COMT binding
- Oxidative Stress — reduced via Nrf2-mediated antioxidant upregulation (HO-1, SOD, catalase)
- pain modulation — enhanced via noradrenergic descending inhibition and reduced inflammatory sensitization
- Quercetin — structurally similar COMT inhibitor with overlapping senolytic properties (contraindicated in same populations)
- EGCG — green tea catechin and potent COMT inhibitor (avoid in Met/Met genotype)
- IL-6 — reduced via NF-κB suppression and SASP clearance (clinical marker for inflammaging)
- Alzheimer's Disease — fisetin shows neuroprotection in AD models via amyloid-β aggregation inhibition and tau phosphorylation reduction
- Depression — potential benefit via BDNF enhancement and dopamine prolongation but risk in catecholamine-sensitive subtypes
- ADHD — therapeutic for inattentive subtype with COMT Val/Val but contraindicated in hyperactive subtype with Met/Met
- Microbiome — gut bacteria metabolize fisetin to bioactive metabolites affecting systemic anti-inflammatory effects